Wells Fargo & Co. reaffirmed their buy rating on shares of MyoKardia Inc. (NASDAQ:MYOK) in a research note published on Thursday.

Analyst Recommendations for MyoKardia (NASDAQ:MYOK)

Several other research analysts have also weighed in on MYOK. Credit Suisse Group AG reaffirmed a buy rating and set a $20.00 target price (up previously from $16.00) on shares of MyoKardia in a research note on Tuesday, July 12th. Zacks Investment Research raised shares of MyoKardia from a sell rating to a hold rating in a research note on Tuesday, August 23rd. Wedbush reaffirmed an outperform rating and set a $22.00 target price on shares of MyoKardia in a research note on Tuesday, August 9th. Finally, BMO Capital Markets began coverage on shares of MyoKardia in a research note on Wednesday, July 20th. They set an outperform rating and a $28.00 target price for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. MyoKardia presently has a consensus rating of Buy and a consensus price target of $23.50.

MyoKardia (NASDAQ:MYOK) opened at 18.01 on Thursday. The company’s market cap is $486.63 million. MyoKardia has a 1-year low of $6.24 and a 1-year high of $22.83. The company’s 50 day moving average is $19.97 and its 200 day moving average is $14.44.

MyoKardia (NASDAQ:MYOK) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.04. MyoKardia had a negative return on equity of 62.91% and a negative net margin of 222.21%. The firm had revenue of $3.55 million for the quarter, compared to analyst estimates of $3.55 million. The business’s quarterly revenue was up .0% compared to the same quarter last year. Equities research analysts forecast that MyoKardia will post ($1.52) EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Teachers Advisors Inc. raised its position in MyoKardia by 185.7% in the second quarter. Teachers Advisors Inc. now owns 18,223 shares of the company’s stock valued at $226,000 after buying an additional 11,845 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its position in MyoKardia by 144.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 83,989 shares of the company’s stock valued at $1,041,000 after buying an additional 49,603 shares during the last quarter. BlackRock Fund Advisors raised its position in MyoKardia by 80.2% in the second quarter. BlackRock Fund Advisors now owns 290,293 shares of the company’s stock valued at $3,600,000 after buying an additional 129,164 shares during the last quarter. BlackRock Investment Management LLC raised its position in MyoKardia by 109.8% in the second quarter. BlackRock Investment Management LLC now owns 42,352 shares of the company’s stock valued at $525,000 after buying an additional 22,169 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in MyoKardia by 130.8% in the second quarter. Vanguard Group Inc. now owns 314,800 shares of the company’s stock valued at $3,904,000 after buying an additional 178,431 shares during the last quarter. 36.67% of the stock is owned by institutional investors and hedge funds.

MyoKardia Company Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that results from biomechanical defects in cardiac muscle contraction. It is engaged in the business of developing and commercializing therapeutics.

5 Day Chart for NASDAQ:MYOK

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.